MXPA01006006A - Cadena receptora de citocina. - Google Patents

Cadena receptora de citocina.

Info

Publication number
MXPA01006006A
MXPA01006006A MXPA01006006A MXPA01006006A MXPA01006006A MX PA01006006 A MXPA01006006 A MX PA01006006A MX PA01006006 A MXPA01006006 A MX PA01006006A MX PA01006006 A MXPA01006006 A MX PA01006006A MX PA01006006 A MXPA01006006 A MX PA01006006A
Authority
MX
Mexico
Prior art keywords
cytokine receptor
receptor chain
methods
receptor
disclosed
Prior art date
Application number
MXPA01006006A
Other languages
English (en)
Inventor
Tamlyn Neben
Original Assignee
Genetics Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22786499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA01006006(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Inst filed Critical Genetics Inst
Publication of MXPA01006006A publication Critical patent/MXPA01006006A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen polinucleotidos que codifican al receptor IL-13 y fragmentos del mismo. Tambien se describen proteinas del receptor IL-13, metodos para su produccion, inhibidores de fijacion del IL-13 y su receptor, y metodos de tratamiento medico que usan tales moleculas y antagonistas de la interaccion del IL-13/IL-13R.
MXPA01006006A 1998-12-14 1999-12-13 Cadena receptora de citocina. MXPA01006006A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21133598A 1998-12-14 1998-12-14
PCT/US1999/029493 WO2000036103A1 (en) 1998-12-14 1999-12-13 Cytokine receptor chain

Publications (1)

Publication Number Publication Date
MXPA01006006A true MXPA01006006A (es) 2004-08-12

Family

ID=22786499

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01006006A MXPA01006006A (es) 1998-12-14 1999-12-13 Cadena receptora de citocina.

Country Status (16)

Country Link
US (1) US7507706B1 (es)
EP (1) EP1141286B1 (es)
JP (3) JP5519087B2 (es)
CN (2) CN104611339A (es)
AT (1) ATE342976T1 (es)
AU (1) AU780031B2 (es)
BR (1) BR9916209A (es)
CA (1) CA2356779C (es)
CY (1) CY1107657T1 (es)
DE (1) DE69933696T2 (es)
DK (1) DK1141286T3 (es)
ES (1) ES2277460T3 (es)
MX (1) MXPA01006006A (es)
NZ (1) NZ512942A (es)
PT (1) PT1141286E (es)
WO (1) WO2000036103A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
AU780031B2 (en) 1998-12-14 2005-02-24 Genetics Institute, Llc Cytokine receptor chain
WO2002055100A2 (en) * 2000-10-20 2002-07-18 Genetics Institute, Llc Method and composition for inhibition of tumor growth and enhancing an immune response
EP1587534A1 (en) * 2003-01-17 2005-10-26 Children's Hospital Medical Center Use of tff2, or agents inducing tff2, in the therapy of allergies
BRPI0406776A (pt) * 2003-01-18 2005-12-27 Childrens Hosp Medical Center Composição farmacêutica, método de avaliação fisiológica e uso de pelo menos um dentre um inibidor de uma molécula semelhante a resistina (alfa) (relm(alfa)), uma molécula semelhante a resistina ß (relmß), um regulador de expressão de relm(alfa) ou um regulador de expressão de relmß
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
WO2004092404A2 (en) * 2003-04-11 2004-10-28 Wyeth Inhibitors of acidic mammalian chitinase as asthma therapeutics
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
SG10201900535UA (en) 2003-12-23 2019-02-27 Genentech Inc Novel anti-il 13 antibodies and uses thereof
WO2005085866A1 (en) * 2004-02-27 2005-09-15 Novartis Ag Screening assay for modulators of interaction between interleukin-12 and/or -23 with their receptors
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
CA2587903A1 (en) 2004-11-17 2006-05-26 Amgen Fremont Inc. Fully human monoclonal antibodies to il-13
EP2532678A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
TW200848429A (en) * 2007-04-23 2008-12-16 Wyeth Corp Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
EP2162743A4 (en) * 2007-05-29 2010-07-14 Univ Cincinnati METHOD FOR MODULATING IGNITION AND COMPOSITIONS THEREFOR
CN107318267B (zh) 2013-08-12 2021-08-17 豪夫迈·罗氏有限公司 用于治疗补体相关的病症的组合物和方法
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
WO2015038888A1 (en) 2013-09-13 2015-03-19 Genentech, Inc. Methods and compositions comprising purified recombinant polypeptides
WO2018195388A1 (en) 2017-04-21 2018-10-25 Kindred Biosciences, Inc. Il4/il13 receptor molecule for veterinary use

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1989004838A1 (en) 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US5359037A (en) 1988-09-12 1994-10-25 Yeda Research And Development Co. Ltd. Antibodies to TNF binding protein I
WO1990005183A1 (en) * 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5011778A (en) 1989-05-23 1991-04-30 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies
AU639754B2 (en) 1989-12-20 1993-08-05 Schering Corporation Antibody antagonists of human interleukin-4
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5246701A (en) 1990-10-05 1993-09-21 Ludwig Institute For Cancer Research Method for inhibiting production of IgE by using IL-9 inhibitors
DK0506574T3 (da) 1991-03-29 1996-04-09 Sanofi Sa Protein med aktivitet af cytokintype, rekombinant-DNA, der koder for dette protein, celler og transformerede mikroorganismer
AU3658093A (en) 1992-02-10 1993-09-03 Seragen, Inc. Desensitization to specific allergens
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
AU5010793A (en) 1992-08-21 1994-03-15 Schering Corporation Human interleukin-13
US5596072A (en) 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
WO1995006481A1 (en) 1993-09-02 1995-03-09 Trustees Of Dartmouth College Methods for inducing antigen-specific t cell tolerance
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
US5696234A (en) 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
ES2334408T3 (es) 1995-10-23 2010-03-09 Zenyth Operations Pty Ltd Receptor de hematopoyetina y secuencias geneticas que lo codifican.
FR2742156A1 (fr) * 1995-12-06 1997-06-13 Sanofi Sa Polypeptide recepteur de l'il-13
SI9720020B (en) 1996-02-09 2001-12-31 Basf Ag Human antibodies that bind human TNF alpha
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
AU2326097A (en) 1996-03-13 1997-10-01 Zymogenetics Inc. Cytokine-receptor expressed in testis cells
EP0812913A3 (en) * 1996-06-12 1999-08-04 Smithkline Beecham Corporation HR-1 receptor, a receptor of the cytokine receptors family
WO1997047742A1 (en) * 1996-06-12 1997-12-18 Smithkline Beecham Corporation Hr-1 receptor
WO1997047741A1 (en) * 1996-06-12 1997-12-18 Smithkline Beecham Corporation Hr-1 receptor
WO1998010638A1 (en) 1996-09-10 1998-03-19 Amrad Operations Pty. Ltd. Therapeutic molecules
GB9625899D0 (en) 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
JP2001508441A (ja) 1997-01-10 2001-06-26 バイオジェン インコーポレイテッド 抗ｃｄ４０ｌ化合物での狼瘡腎炎の処置
US6387615B2 (en) * 1997-04-11 2002-05-14 Isis Innovation Limited Methods and materials for the diagnosis or prognosis of asthma
GB9723553D0 (en) 1997-11-07 1998-01-07 Duff Gordon W Prediction of the risk of chronic obstructive airway disease
BR9813365A (pt) 1997-12-05 2004-06-15 Scripps Research Inst Método para produção e humanização de um anticorpo monoclonal de rato
AU780031B2 (en) 1998-12-14 2005-02-24 Genetics Institute, Llc Cytokine receptor chain
AU5756100A (en) 1999-06-21 2001-01-09 Genetics Institute Inc. Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains
AU2000278349A1 (en) 1999-09-28 2001-04-30 Genaissance Pharmaceuticals, Inc. Drug target isogenes: polymorphisms in the interleukin 13 gene
CA2386248A1 (en) 1999-10-06 2001-04-12 The Penn State Research Foundation Il13 mutants
US6846486B1 (en) 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
ES2614260T3 (es) 2000-05-26 2017-05-30 Immunex Corporation Uso de anticuerpos contra el receptor de interleuquina-4 y composiciones de los mismos

Also Published As

Publication number Publication date
JP5519087B2 (ja) 2014-06-11
PT1141286E (pt) 2007-01-31
DK1141286T3 (da) 2007-02-19
CA2356779A1 (en) 2000-06-22
JP2010263889A (ja) 2010-11-25
EP1141286A4 (en) 2002-06-26
BR9916209A (pt) 2001-12-26
CN1352686A (zh) 2002-06-05
US7507706B1 (en) 2009-03-24
CN104611339A (zh) 2015-05-13
ES2277460T3 (es) 2007-07-01
ATE342976T1 (de) 2006-11-15
JP2014113165A (ja) 2014-06-26
CA2356779C (en) 2012-03-13
DE69933696T2 (de) 2007-08-23
AU780031B2 (en) 2005-02-24
EP1141286B1 (en) 2006-10-18
DE69933696D1 (de) 2006-11-30
AU2177500A (en) 2000-07-03
CY1107657T1 (el) 2013-04-18
WO2000036103A9 (en) 2002-04-11
WO2000036103A1 (en) 2000-06-22
EP1141286A1 (en) 2001-10-10
JP2003511007A (ja) 2003-03-25
NZ512942A (en) 2004-01-30

Similar Documents

Publication Publication Date Title
MXPA01006006A (es) Cadena receptora de citocina.
MY150237A (en) Cripto blocking antibodies and uses thereof
MY169308A (en) Treatment of tnf? related disorders
DE69840699D1 (de) Heregulin varianten
EP1408986A4 (en) PROTEOMIMETIC COMPOUNDS AND CORRESPONDING METHODS
ZA200604605B (en) Antibodies that bind interleukin-4 receptor
NO20011759L (no) Flt4 (VEGFR-3) som målmateriale for tumor-avbildning og anti- tumor-terapi
NO985574L (no) FremgangsmÕter og preparater anvendelige for inhibering av angiogenese
EP1034188A4 (en) METHOD FOR DESIGNING ANGONISTS AND IGF RECEPTOR ANTAGONISTS
HK1018910A1 (en) Modulators of the receptor associated factor(traf), their preparation and use.
EP1566440A3 (en) Human Interleukin-11 Receptor
TNSN04015A1 (en) Combination therapy for the treatment of cancer
DE60128701D1 (en) Claudin polypeptide
NZ315514A (en) Tumour necrosis factor associated factor (traf) inhibitors including traf polypeptide, murine nucleotide sequence and associated assays
AU6308801A (en) Mu-1, member of the cytokine receptor family
UA72875C2 (uk) БІЛКИ, ЯКІ ЗВ'ЯЗУЮТЬСЯ З <font face="Symbol">b</font>-АМІЛОЇДНИМ ПЕПТИДОМ ТА ПОЛІНУКЛЕОТИДИ, ЩО ЇХ КОДУЮТЬ
EP1255110A3 (en) Methods and products for identifying modulators of P2X7 receptor activity, and their use in the treatment of skeletal disorders
PE20399A1 (es) Muteina ob
IL149045A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
WO2002057433A3 (de) Hipk-kinasen zur verwendung in der beeinflussung von zellteilung und zellproliferation
WO2002000826A3 (fr) Nouveau polypeptide, proteine humaine de methylation d'adn, et polynucleotide codant ce polypeptide
DE69836971D1 (de) Methode und apparat zur vorhersage von funktionellen proteindomänen, methode zur verbesserung der proteinfunktion, sowie funktionell verbessertes protein
ATE329035T1 (de) Cytoplasmische tyrosin kinase
WO2001096524A3 (fr) Nouveau polypeptide, recepteur humain sigma 10.67, et polynucleotide codant ce polypeptide
TW200635950A (en) Specific binding agents of human angiopoietin-2

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: INVISTA TECHNOLOGIES S.A.R.L.

FG Grant or registration
MM Annulment or lapse due to non-payment of fees